drugset / Trial / NCT01946646
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether combination of TS-1 and concurrent and short-course radiotherapy is feasible in metastatic pancreatic cancer. The rationale of this study primarily bases on the good efficacy of gemcitabine plus TS-1 and the great potential of local control of concurrent chemoradiotherapy in pancreatic cancer.
Timeline
- Start
- 2013-10
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | 25 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 30 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 35 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |